News
-
Update on Pharmacoeconomics in the Irish Healthcare Setting 2020
Given the ongoing Covid-19 outbreak , the NCPE Annual Symposium “Update on Pharmacoeconomics in the Irish Healthcare Setting” is being postponed until later this year.
-
Annual NCPE Course
Update on Pharmacoeconomics in the Irish Healthcare Setting, 15th & 16th May 2019 in Dublin Castle. Online access to slides please click here.
-
Idebenone (Raxone®)
The NCPE recommends that idebenone not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
-
Teduglutide (Revestive®)
The NCPE does not recommend reimbursement of Teduglutide (Revestive®) for the treatment of patients aged 1 year and above with short bowel syndrome.
-
Patient Education Programme
The NCPE are delighted to facilitate the delivery of the HTA module of the IPPOSI Pilot Patient Education Programme, commencing this Monday 22nd January. This module will provide students with a detailed knowledge of the principals of HTA, and has been adapted by the NCPE to provide particular insight into […]
-
Mepolizumab (Nucala®) 100mg powder for solution for injection
Following NCPE assessment of mepolizumab (Nucala®) it is not considered cost-effective and therefore is not recommended for reimbursement at the submitted price.
-
Apremilast (Otezla®)
The NCPE does not recommend reimbursement of Apremilast (Otezla®) for psoriatic arthritis at the submitted price.
-
Idelalisib (Zydelig®)
The NCPE do not recommend reimbursement of Idelalisib (Zydelig®)
-
Apremilast (Otezla®)
Reimbursement not recommended at the submitted price.
-
Lixisenatide (Lyxumia®)
The NCPE does not recommend reimbursement of lixisenatide for patients with type 2 diabetes mellitus at the submitted price.
